Business Context and Reporting Period
This Form 8-K Current Report was filed by Aquestive Therapeutics, Inc. on November 7, 2024, covering events occurring on November 1, 2024. The filing addresses corporate governance changes specifically regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 regarding officer departures and appointments and contains no financial data.
Material Changes
The primary material change reported is the resignation of Santo J. Costa from the Board of Directors and his role as Chairman of the Compensation Committee, effective November 4, 2024. Consequently, the Board size will be reduced from eight to seven directors. The filing explicitly states that Mr. Costa's resignation is for personal reasons and does not result from any disagreement with the Company regarding operations, policies, or practices.
Outlook and Management Commentary
Management has announced the following appointments effective November 4, 2024:
- John S. Cochran will serve as the new Chair of the Compensation Committee.
- Timothy E. Morris will be appointed to the Compensation Committee.
The Company expressed gratitude for Mr. Costa's years of service. No financial guidance, risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Resignation of Santo J. Costa is effective November 4, 2024.
- Board of Directors size is reduced from 8 to 7 members.
- John S. Cochran assumes the role of Compensation Committee Chair.
- Timothy E. Morris joins the Compensation Committee.
- No disagreement with the Company was cited as a reason for the resignation.